Piramal starts Phase I study on diabetes compound in Canada
This article was originally published in Scrip
Executive Summary
Piramal Life Sciences, the spun-off R&D entity of the Piramal Group of India, has begun Phase I trials of an experimental compound for diabetes-metabolic syndrome in Canada. P2202, the second compound from Lilly, is being developed under a collaborative agreement between the two companies. A Phase I study of P2202 has been initiated in healthy volunteers to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of the compound. In animal studies, P2202 was shown to lower glucose levels, triglycerides and total cholesterol, and to decrease plaque area animals with atherosclerosis. Last year, Piramal Life Sciences began a Phase I study of an orally active glucose-lowering compound (codenamed P1736) in the Netherlands.